Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 4/20 | 0.92 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL5203458 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL71524 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL71525 | 0.96 | SLC22A1 (1.00) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL22384 | 0.96 | SLC22A1 (1.00) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL2007037 | 0.96 | SLC22A1 (1.00) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL25266692 | 0.92 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL4260120 | 0.92 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL1782492 | 0.92 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL5069703 | 0.92 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL1250868 | 0.92 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015051141-A1 | METHODS FOR PREPARATION OF FLUORINATED SULFUR-CONTAINING COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-04-09 | — | — | WO | claimed |
| US-12234232-B2 | Aromatic heterocyclic compound with kinase inhibitory activity | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2025-02-25 | — | — | US | disclosed |
| CN-109643822-B | Nonaqueous electrolyte composition comprising fluorinated sulfone | 索尔维公司 | 2023-04-28 | — | — | CN | disclosed |
| US-11374260-B2 | Nonaqueous electrolyte compositions comprising fluorinated sulfones | SYENSQO SA (BE) | 2022-06-28 | — | — | US | disclosed |
| US-20210371415-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3465811-B1 | NONAQUEOUS ELECTROLYTE COMPOSITIONS COMPRISING FLUORINATED SULFONES | SOLVAY (BE) | 2021-09-29 | — | — | EP | disclosed |
| EP-3854793-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
| US-10816716-B2 | Application of quantum dot composite material | LEXTAR ELECTRONICS CORPORATION (TW) | 2020-10-27 | — | — | US | disclosed |
| US-20200321657-A1 | NONAQUEOUS ELECTROLYTE COMPOSITIONS COMPRISING FLUORINATED SULFONES | SYENSQO SA (BE) | 2020-10-08 | — | — | US | disclosed |
| WO-2020057669-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | 上海轶诺药业有限公司 | 2020-03-26 | — | — | WO | disclosed |
| US-20170153382-A1 | QUANTUM DOT COMPOSITE MATERIAL AND MANUFACTURING METHOD AND APPLICATION THEREOF | LEXTAR ELECTRONICS CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| WO-2015051141-A1 | METHODS FOR PREPARATION OF FLUORINATED SULFUR-CONTAINING COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-1434758-B1 | AMINONITRILE PRODUCTION | INVISTA TECH SARL (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1816120-A1 | Aminonitrile production | INVISTA Technologies S.à.r.l. (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1434758-A1 | AMINONITRILE PRODUCTION | INVISTA Technologies S.à.r.l. (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003029192-A1 | AMINONITRILE PRODUCTION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| US-6455723-B1 | Aminonitrile production | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-09-24 | — | — | US | disclosed |
| EP-1212096-A2 | DRUG CONJUGATES AND METHODS OF DESIGNING THE SAME | Brenner, Sydney (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001013958-A2 | DRUG CONJUGATES AND METHODS OF DESIGNING THE SAME | BRENNER SYDNEY (US) | 2001-03-01 | — | — | WO | disclosed |
| US-3974066-A | Removal of oxygen from petroleum charge stocks | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371415-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | JAK1, JAK2, JAK3 | SLC22A1 4309/4885SLC22A2 4537/4885TSHR 2399/4885 |
| US-12234232-B2 | Aromatic heterocyclic compound with kinase inhibitory activity | JAK1, JAK2, JAK3 | SLC22A1 4309/4885SLC22A2 4537/4885TSHR 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.